Financial Data and Key Metrics Changes - Global sales for Q2 were $936 million, a decrease of 5% as reported or a negative 7% on a constant currency basis, with adjusted EBITDA margin at 21%, increasing 360 basis points year-over-year [13][20][21] - Adjusted earnings per share were $0.52, growing 7% compared to the prior year, driven primarily by active cost reduction programs [14][21] - Cash flow from operations was $48 million for the quarter, with a net debt to EBITDA ratio of 3.1 times [22][21] Business Line Data and Key Metrics Changes - EDS (Endo, Resto, and preventative products) saw a constant currency sales increase of 1.1%, while OIS (Orthodontic and Implant Solutions) sales declined 19.4% due to lower lab volumes globally [23][24] - CTS (Connected Technology Solutions) sales fell 5.9% in constant currency, with double-digit growth in imaging in Europe offset by declines in CADCAM and imaging in the U.S. [24] - Wellspect Healthcare sales declined 2.5%, impacted by prior year dealer stocking orders [25] Market Data and Key Metrics Changes - U.S. sales in Q2 were $293 million, down 18% in total or 11% excluding the BiTE impact, primarily due to softness in connected technology solutions and orthodontic and implant solutions [15] - European sales were approximately flat year-over-year, with Germany showing growth driven by CTS and SureSmile, which was up over 27% [16] - Rest of world sales were $239 million, up slightly year-over-year, with growth in essential dental solutions and SureSmile [16] Company Strategy and Development Direction - The company aims to enhance customer experience and support through simplified interactions and increased strategic investments [11][12] - Focus on innovation and speed to market is emphasized, with the DS Core platform gaining traction among users [11][12] - The company plans to streamline operations to unlock value and reduce costs, redirecting funds into sustained profitable growth [12][27] Management's Comments on Operating Environment and Future Outlook - Management noted that global patient volumes and procedures remained largely unchanged, with a focus on long-term strategies rather than short-term fluctuations [31][32] - The company maintains its full-year 2025 outlook for sales, adjusted EBITDA margin, and adjusted EPS despite current challenges [25][27] - Management is cautious about the impact of tariffs, with an updated annualized impact now estimated at $80 million [48][49] Other Important Information - A non-cash after-tax charge of approximately $214 million was recorded related to the impairment of goodwill and other intangible assets [21] - The company completed a $550 million hybrid bond offering in Q2, enhancing financial flexibility [22] Q&A Session Summary Question: Overview of the broader dental market - Management indicated that patient volumes remain stable, but procedural utilization in elective areas like implants and ortho continues to be soft, with a focus on long-term strategies [30][31] Question: Distributor stock dynamics - Management noted no significant revenue impact from distributor stock changes, with healthy positions in imaging and CADCAM [34][35] Question: Motivation for joining Dentsply - The new CEO expressed a desire to apply operational experience and execution strategies learned from previous roles to enhance Dentsply's performance [38][39] Question: Performance of implants - Management highlighted a decline in premium implants due to shifts from legacy brands, with expectations for growth driven by sales force changes and new consumer experiences [41][44] Question: Tariff assumptions - The annualized impact of tariffs has increased to about $80 million, with ongoing efforts to mitigate costs through supply chain efficiencies [47][48] Question: Adjustments on BiTE - A $4 million adjustment was noted for BiTE in Q2, with no further changes anticipated for the second half of the year [51] Question: Portfolio assessment and growth strategy - Management believes there are no major gaps in the portfolio, focusing on organic growth while remaining open to opportunistic acquisitions [56][58] Question: Confidence in value implants - Management acknowledged challenges in the value implant segment due to Middle East volatility but expects performance to improve in the second half of the year [88][89]

Financial Data and Key Metrics Changes - Global sales for Q2 were $936 million, a decrease of 5% as reported or a negative 7% on a constant currency basis, with adjusted EBITDA margin at 21%, increasing 360 basis points year-over-year [12][20] - Adjusted earnings per share were $0.52, growing 7% compared to the prior year, driven primarily by active cost reduction programs [12][20] - Cash flow from operations was $48 million for the quarter, a decline from $28 million in the prior year quarter [21] Business Line Data and Key Metrics Changes - EDS (Endo, Resto, and preventative products) sales increased 1.1% on a constant currency basis, with growth in the rest of the world, but lower volumes in Europe and the US [22] - OIS (Orthodontic and Implant Solutions) sales declined 19.4% in constant currency, with BiTE accounting for over half of the decline [22] - CTS (Connected Technology Solutions) sales fell 5.9% in constant currency, with double-digit growth in imaging in Europe offset by declines in CADCAM and imaging in the US [22] Market Data and Key Metrics Changes - US sales in Q2 were $293 million, down 18% in total or 11% excluding the BiTE impact, primarily driven by softness in connected technology solutions and orthodontic and implant solutions [14] - European sales were approximately $400 million, flat compared to Q2 of the prior year, with Germany showing growth driven by CTS and SureSmile, which was up over 27% [15] - Rest of world sales were $239 million, slightly up versus the prior year, with growth in essential dental solutions and SureSmile up double digits [15] Company Strategy and Development Direction - The company aims to enhance customer experience and support through simplified interactions and increased strategic investments [10] - Focus on innovation and speed to market, with a goal to shape the future of markets by partnering with practitioners [10] - The DS Core platform is a critical element of the strategy, with 50,000 unique users and increasing connected devices and lab orders processed [10] Management's Comments on Operating Environment and Future Outlook - Management noted that global patient volumes and procedures remained largely unchanged, with a focus on long-term strategies rather than short-term market fluctuations [32] - The company is maintaining its full-year 2025 outlook for sales, adjusted EBITDA margin, and adjusted EPS despite current challenges [26] - Management emphasized the importance of focusing on customer needs and improving execution to drive growth [95] Other Important Information - The company recorded a non-cash after-tax charge of approximately $214 million related to the impairment of goodwill and other intangible assets within the OIS and CCS segments [20] - The company completed a $550 million hybrid bond offering in Q2, enhancing financial flexibility [21] Q&A Session Summary Question: Overview of the broader dental market - Management indicated that patient volumes remain stable, but procedural utilization in elective areas like implants and ortho continues to be soft, with a focus on long-term strategies [31] Question: Distributor stock dynamics - Management noted no significant revenue impact from distributor stock changes, with healthy positions in imaging and CADCAM [34] Question: Motivation for joining Dentsply - The new CEO expressed interest in applying operational experience to enhance Dentsply's performance and accelerate growth [39] Question: Performance of implants - Management reported a decline in premium implants due to the transition from legacy brands, with expectations for growth driven by sales force changes and new consumer experiences [43] Question: Tariff assumptions - The annualized impact of tariffs has increased from $50 million to $80 million, with ongoing efforts to mitigate costs through supply chain efficiencies [48] Question: Adjustments on BiTE - A $4 million adjustment was noted for BiTE in Q2, with no further changes anticipated for the second half of the year [52] Question: Portfolio assessment - The CEO believes Dentsply is well-positioned in the market, with a focus on organic growth while remaining open to opportunistic acquisitions [58] Question: Market share dynamics in implants - Management acknowledged challenges in the value implant segment due to Middle East volatility but expects stronger performance in the second half of the year [90]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-16211 DENTSPLY SIRONA Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation ...

Financial Performance - Net sales were $936 million, a decrease of 4.9% year-over-year[12] - Constant currency net sales decreased by 6.7% year-over-year, including a 3.2% impact from Byte[10, 14] - Adjusted EBITDA was $197 million, a 14.6% increase year-over-year, with a margin of 21.1%, up 360 bps year-over-year[12, 14] - Adjusted EPS was $0.52, a 6.6% increase year-over-year[10, 14] - Operating cash flow was $48 million, a 77% decrease year-over-year[12] Segment Performance - Essential Dental Solutions (EDS) sales were $387 million, a reported increase of 2.9% and a constant currency increase of 1.1%[17] - Orthodontic and Implant Solutions (OIS) sales were $226 million, a reported decrease of 18.1% and a constant currency decrease of 19.4%, including a ~$35 million Byte impact[17] - Connected Technology Solutions (CTS) sales were $243 million, a reported decrease of 3.8% and a constant currency decrease of 5.9%[17] - Wellspect Healthcare sales were $80 million, a reported increase of 1.2% and a constant currency decrease of 2.5%, including a ~4.5% impact from prior year U S distributor initial stocking order[17] Regional Performance - U S net sales were $293 million, a constant currency decrease of 18.3%, including a 7.7% Byte impact[10] - Europe net sales were $404 million, a constant currency decrease of 0.4%[10] - Rest of World net sales were $239 million, a constant currency increase of 0.5%[10] Outlook - The company reaffirmed its FY2025 outlook, with constant currency growth between (4.0%) and (2.0%), including a (2.0%) Byte impact[19] - The company reaffirmed its FY2025 outlook, with reported sales between $3.60 billion and $3.70 billion[19] - The company reaffirmed its FY2025 outlook, with adjusted EBITDA margin greater than 19% and adjusted EPS between $1.80 and $2.00[19]

Leadership transition with Dan Scavilla appointed CEO effective August 1, 2025 and Matt Garth appointed CFO effective May 30, 2025 CHARLOTTE, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the second quarter of 2025. Second quarter net sales of $936 million decreased (4.9%) (decreased (6.7%) in constant currency) compared to the second quarter of 2024. Foreign currency changes positively impacted seco ...

登士柏西诺德生产的XiVE S系列纯钛植体，自2017年2月起 在中国注册为钛四级（TA4），但后经第三方检测，部分抽检 样本实际使用的材料却是钛二级（TA2G）。 作者： 田国宝 封图：图虫创意 登士柏西诺德（Dentsply Sirona）被指将材质为二级纯钛的人工牙种植体以四级名义对外销售，这一行为令经销商、牙科医院始料未及，并引发了他 们对未来潜在风险的担忧。 登士柏西诺德由美国登士柏和德国西诺德于2016年合并成立，业务遍及全球40多个国家。其中，登士柏成立于1899年，西诺德成立于1877年。每年有 超过60万名牙科专业人员使用登士柏西诺德的产品和解决方案，为约600万名患者提供治疗。 涉事产品为登士柏西诺德生产的XiVE S系列纯钛种植体。该系列自2017年2月起在中国注册为钛四级（TA4），但后经第三方检测，部分抽检样本实际 使用的材料却是钛二级（TA2G）。 2024年2月，登士柏西诺德将XiVE S系列产品注册材质变更为钛二级。 多位牙科医生告诉经济观察报，目前临床上使用的纯钛种植牙多为四级、五级。 登士柏西诺德的中国代理商北京盛源鸿康医疗科技有限公司（下称"盛源鸿康"）向经济观察报表示， ...

Core Insights - DENTSPLY SIRONA Inc. is set to release its second-quarter 2025 results on August 7, with expectations of revenue at $851.6 million and earnings at 29 cents per share [2][3] Group 1: Q2 Performance Expectations - The company has shown an average earnings surprise of 2.73% over the past four quarters, indicating a potential for positive performance [2] - The Imaging segment is expected to benefit from the relaunch of Orthophos SL and Primescan 2, which may have driven growth, particularly in Europe and APAC [4] - Orthodontics, particularly SureSmile, is anticipated to show stable global growth, although U.S. performance may be hindered by softer discretionary spending [5] Group 2: Challenges and Headwinds - The suspension of Byte aligner sales is projected to negatively impact organic sales by approximately two percentage points in 2025, affecting second-quarter results as well [6] - Essential Dental Solutions may have experienced stable patient traffic, but overall segment growth is likely to be limited by softness in elective procedures and weak U.S. implant sales [7] - Connected Technology Solutions, including CAD/CAM, continues to face macroeconomic pressures, with subdued retail demand in the U.S. despite growth in Germany [8] Group 3: Operational Insights - DENTSPLY SIRONA's Phase II transformation activities are on track to deliver full run-rate savings by the end of 2025, with expectations of gradual stabilization in gross margins throughout the year [9] - Cost initiatives and SKU rationalization may contribute to improved gross margins, aiding quarter-over-quarter growth in Q2 [11] Group 4: Earnings Prediction Model - The current model does not predict an earnings beat for DENTSPLY SIRONA, with an Earnings ESP of -0.99% and a Zacks Rank of 2 [12][13]

Core Viewpoint - Dentsply International is anticipated to report a year-over-year increase in earnings despite a decline in revenues, with the actual results being crucial for the stock's near-term price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected to be released on August 7, with a consensus estimate of $0.51 per share, reflecting a +4.1% change year-over-year. Revenues are projected to be $933.1 million, down 5.2% from the previous year [3][2]. Estimate Revisions - The consensus EPS estimate has been revised 0.47% lower in the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Dentsply is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.99%. This suggests a bearish outlook from analysts [12]. Historical Performance - In the last reported quarter, Dentsply exceeded the expected earnings of $0.29 per share by delivering $0.43, resulting in a surprise of +48.28%. Over the last four quarters, the company has beaten consensus EPS estimates two times [13][14]. Investment Considerations - While Dentsply does not appear to be a strong candidate for an earnings beat, investors are advised to consider other factors influencing stock performance ahead of the earnings release [17].

Employment Agreement This agreement details the terms of employment, compensation, termination, and restrictive covenants for the President and CEO [1. Employment](index=1&type=section&id=1.%20Employment) The agreement establishes the executive's role, a three-year initial term, duties, and primary location of employment - The employment term begins on August 1, 2025, for an **initial period of three years**[7](index=7&type=chunk) - The agreement will **automatically renew for successive 12-month periods** unless either party provides a 90-day notice of non-renewal[7](index=7&type=chunk) - Executive will serve as the **President and Chief Executive Officer** of the Company, reporting to the Board of Directors[8](index=8&type=chunk) - Executive must devote substantially all working time to the company but is permitted to manage personal affairs, serve on non-profit boards, and, with Board approval, serve on one other public or private company board[8](index=8&type=chunk) - The executive's principal office will be at the Company's commercial headquarters in **Charlotte, North Carolina**[10](index=10&type=chunk) [2. Compensation and Related Matters](index=2&type=section&id=2.%20Compensation%20and%20Related%20Matters) The executive's compensation package includes base salary, annual bonuses, long-term incentives, and one-time initial grants Annual Base Salary | Component | Amount | | :--- | :--- | | Annual Base Salary | $1,030,000 | Annual Bonus Target | Component | Target | | :--- | :--- | | Annual Bonus | 135% of Annual Base Salary | - For fiscal year 2025, the annual bonus will be prorated, and performance will be deemed achieved at the **greater of 75% of target** or the multiplier based on actual full-year performance[14](index=14&type=chunk) Annual Long-Term Incentive Target | Component | Target Value | | :--- | :--- | | Annual Equity Incentive (starting FY2026) | $7,750,000 | Initial Equity Grants | Grant Type | Grant Date Value | | :--- | :--- | | **Total Initial Grants** | **~$6,400,000** | | Pro-rata Annual Grant | $3,875,000 | | Inducement Grant | $2,525,000 | | Option Initial Grant (50% of total) | $3,200,000 | | PSU Initial Grant (50% of total) | $3,200,000 | - The Option Initial Grant vests in **three substantially equal annual installments**, beginning on the first anniversary of the Commencement Date[17](index=17&type=chunk) - The PSU Initial Grant vests based on **time and performance conditions** similar to those for other executive officers' FY25 PSU awards[18](index=18&type=chunk) Signing Bonuses | Bonus Type | Amount/Formula | | :--- | :--- | | Relocation Signing Bonus | $150,000 | | Additional Signing Bonus | $1,600,000 multiplied by the fraction of 2025 prior to the start date | - Signing bonuses may be required to be repaid if the executive's employment is terminated by the Company for Cause or by the Executive without Good Reason before the first anniversary of the start date[22](index=22&type=chunk) [3. Termination](index=5&type=section&id=3.%20Termination) The agreement defines conditions for employment termination and outlines baseline payment obligations and required resignations - Employment can be terminated under the following circumstances: **Death, Disability, by the Company for Cause, by the Company without Cause, by the Executive without Good Reason, or by the Executive for Good Reason**[28](index=28&type=chunk)[29](index=29&type=chunk) - Upon any termination, the executive (or their estate) is entitled to receive **earned but unpaid Annual Base Salary, reimbursement for business expenses, and any vested employee benefits**[31](index=31&type=chunk) - Upon termination of employment for any reason, the Executive is **deemed to have resigned from all offices and directorships** held with the Company or its Affiliates[32](index=32&type=chunk)[33](index=33&type=chunk) [4. Severance](index=7&type=section&id=4.%20Severance) The executive is eligible for severance under the company's plan, contingent on a release of claims - The Executive is eligible to participate in the company's Key Employee Severance Benefits Plan, with benefits **contingent on signing and not revoking a release of claims**[35](index=35&type=chunk) - If employment is terminated due to death or Disability, the executive (or their estate) will receive a **prorated Annual Bonus** for the fiscal year in which termination occurs, based on actual company performance[36](index=36&type=chunk) - Severance benefits under this agreement are **not intended to duplicate other benefits**, and the company may reduce payments to avoid duplication[37](index=37&type=chunk) [5. Covenants](index=8&type=section&id=5.%20Covenants) The agreement establishes a 24-month post-termination non-compete, non-solicitation, and mutual non-disparagement covenants - The "Restriction Period" for covenants is defined as the period of employment plus **twenty-four (24) months** following the date of termination[41](index=41&type=chunk) - During the Restriction Period, the executive is **prohibited from being employed by or acting as a senior advisor to any Competing Business**[38](index=38&type=chunk) - The executive is **prohibited from soliciting company customers or employees** during the Restriction Period[39](index=39&type=chunk) - The agreement includes a **mutual non-disparagement clause**, binding on both the executive and the company's officers and directors[42](index=42&type=chunk) [6. Nondisclosure of Proprietary Information](index=10&type=section&id=6.%20Nondisclosure%20of%20Proprietary%20Information) The executive has a perpetual obligation to protect the company's confidential information and return all property upon termination - The executive must, **in perpetuity, maintain the confidence of and not use or disclose the Company's Confidential Information**, which includes a broad range of business, financial, and technical information[46](index=46&type=chunk) - Upon termination, the executive must **promptly return all company documents and property**, in any form, that contain Confidential Information[47](index=47&type=chunk) - The agreement provides **immunity under the Defend Trade Secrets Act** (18 U.S.C. § 1833(b)) for disclosing a trade secret to a government official or an attorney solely for the purpose of reporting or investigating a suspected violation of law[51](index=51&type=chunk) [7. Inventions](index=11&type=section&id=7.%20Inventions) All inventions created by the executive during employment related to the company's business are its exclusive property - All rights to discoveries, inventions, improvements, and innovations related to the company's business created by the executive during employment ("Inventions") are the **exclusive property of the Company**[52](index=52&type=chunk) - The executive must **promptly disclose all Inventions** to the Company and assist the Company in obtaining, defending, and enforcing its rights, even after employment ends[52](index=52&type=chunk)[53](index=53&type=chunk) [8. Injunctive Relief](index=12&type=section&id=8.%20Injunctive%20Relief) The company is entitled to seek injunctive relief for breaches of covenants without posting a bond - A breach of the covenants in Sections 5-7 is acknowledged to cause **irreparable damage** to the Company[54](index=54&type=chunk) - In the event of such a breach, the Company is entitled to seek **specific performance and injunctive relief** without the requirement to post a bond[54](index=54&type=chunk) [9. Clawback Provisions](index=12&type=section&id=9.%20Clawback%20Provisions) All incentive-based compensation is subject to clawback as required by company policy, law, or exchange listing rules - Any incentive-based compensation paid to the Executive is **subject to deduction and clawback** as may be required by Company policy, law, government regulation, or stock exchange listing requirements[55](index=55&type=chunk) [10. Section 280G](index=12&type=section&id=10.%20Section%20280G) Parachute payments will be structured to maximize the executive's after-tax benefit by either paying in full or reducing to avoid excise tax - If any payments in connection with a Change in Control would constitute a "parachute payment" under Section 280G of the Code, the total payment will be either delivered in full or reduced to avoid the excise tax, **whichever results in the greatest after-tax amount for the Executive**[56](index=56&type=chunk) [11. Assignment and Successors](index=13&type=section&id=11.%20Assignment%20and%20Successors) The company may assign the agreement to a successor, while the executive's rights are generally non-assignable - The Company may assign its rights and obligations to a successor or a U.S. subsidiary; **The Executive's rights and obligations are not assignable**[58](index=58&type=chunk) - The Executive may designate a beneficiary to receive compensation due after his death[58](index=58&type=chunk) [12. Certain Definitions](index=13&type=section&id=12.%20Certain%20Definitions) This section defines key terms used in the agreement, referencing the company's Severance Plan for several definitions - Defines key terms used in the agreement; **"Cause" and "Good Reason" are defined by referencing the company's Current Severance Plan**[59](index=59&type=chunk)[61](index=61&type=chunk) [13. Miscellaneous Provisions](index=14&type=section&id=13.%20Miscellaneous%20Provisions) This section contains standard legal clauses, including governing law and provisions to ensure compliance with Section 409A - The agreement is governed by the laws of the **State of North Carolina**[61](index=61&type=chunk) - The provisions of **Sections 4 through 11 and Section 13 will survive** the termination of employment[62](index=62&type=chunk) - The agreement is intended to comply with **Section 409A of the Internal Revenue Code**, and payments may be delayed for six months if the executive is a "specified employee"[71](index=71&type=chunk)[72](index=72&type=chunk)[73](index=73&type=chunk) Exhibit A: Separation and Release of Claims Agreement This exhibit outlines the terms of separation, a comprehensive release of claims, and related legal provisions [1-4. Separation Terms and Benefits](index=19&type=section&id=1-4.%20Separation%20Terms%20and%20Benefits) These sections formalize the separation date, property return, and the executive's entitlement to severance benefits - The agreement sets forth the terms of the Executive's separation from employment as of the **"Separation Date"**[82](index=82&type=chunk) - The Executive must **return all Employer property within five business days** of the Separation Date[83](index=83&type=chunk) - In exchange for signing the agreement, the Executive will receive the **severance payments and benefits** specified in the Employment Agreement and the Severance Plan[85](index=85&type=chunk) [5. Release](index=20&type=section&id=5.%20Release) The executive provides a broad, irrevocable waiver of all known and unknown claims against the company, with specific exceptions - The Executive provides a **full and unconditional release of all claims** against the Employer and its affiliates ("Released Parties") arising up to the date of signing[87](index=87&type=chunk) - The release specifically covers claims under numerous laws, including **Title VII, ADA, FMLA, ERISA**, and various other federal and state statutes[87](index=87&type=chunk) - The release **does not waive certain rights**, including: the right to file a charge with the EEOC, claims for vested benefits, rights under this agreement, and indemnification rights[89](index=89&type=chunk) [6. Specific Release of ADEA Claims](index=21&type=section&id=6.%20Specific%20Release%20of%20ADEA%20Claims) This section ensures the waiver of age discrimination claims is knowing and voluntary, providing review and revocation periods - The Executive specifically waives and releases all claims arising under the **Age Discrimination in Employment Act (ADEA)**[90](index=90&type=chunk)[91](index=91&type=chunk) - The agreement confirms the Executive was given at least **twenty-one (21) days to consider** the terms and has a **seven (7) day period after signing to revoke** the ADEA release[91](index=91&type=chunk) [7-10. Agreement Mechanics and Enforcement](index=22&type=section&id=7-10.%20Agreement%20Mechanics%20and%20Enforcement) These sections detail the agreement's effective date, confidentiality, and the company's remedies for a breach by the executive - The agreement becomes effective on the **eighth day after the Executive signs**, provided it is not revoked during the 7-day Revocation Period[92](index=92&type=chunk) - The Executive reaffirms their obligation to comply with all **post-termination obligations and restrictive covenants** from the original Employment Agreement[93](index=93&type=chunk) - The Executive agrees to **keep the terms of the agreement confidential**, with exceptions for disclosures to a spouse, attorney, and tax advisors[94](index=94&type=chunk) - If the Executive breaches the agreement, the Company is entitled to seek **injunctive relief and may terminate any further severance payments**[96](index=96&type=chunk) [11-22. General Legal Provisions](index=24&type=section&id=11-22.%20General%20Legal%20Provisions) This final part contains standard legal clauses, including governing law, an entire agreement clause, and no admission of liability - The agreement is governed by the laws of **North Carolina**, with jurisdiction in Charlotte[98](index=98&type=chunk) - The agreement **does not constitute an admission of wrongdoing or liability** by either the Employer or the Executive[103](index=103&type=chunk) - The agreement is intended to comply with **Section 409A of the Internal Revenue Code**, and payments may be structured or delayed to ensure compliance[105](index=105&type=chunk)[106](index=106&type=chunk)

Leadership Transition - Dentsply Sirona has appointed Daniel Scavilla as President and CEO, effective August 1, 2025, succeeding Simon Campion who will leave the company on July 31, 2025 [1][3] - Scavilla has over three decades of experience in the medical technology and pharmaceutical industries, previously serving as CEO of Globus Medical and holding various leadership roles at Johnson & Johnson [2][8] - The Board of Directors expresses confidence in Scavilla's ability to enhance shareholder value and lead the company through its transformation [3] Financial Performance - Dentsply Sirona expects to report second quarter 2025 net sales of approximately $935 million, with adjusted earnings per diluted share anticipated to be between $0.50 and $0.52 [5] - The company reaffirmed its 2025 outlook as provided in the May 8, 2025 earnings press release, indicating ongoing confidence in its financial trajectory [6] Company Overview - Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with a strong portfolio of brands and a commitment to innovation in dental care [9]